Compare Johnson & Johnson (JNJ) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vertiv Holdings Co — how do they compare? Johnson & Johnson trades at $256.16 (market cap $622.84B), while Vertiv Holdings Co trades at $248.9 (market cap $94.90B). The key difference: Johnson & Johnson is far larger — about 6.6× Vertiv Holdings Co's market cap, and Johnson & Johnson pays the higher dividend (2.07%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vertiv Holdings Co for 39 Days on average.
| JNJ | VRT | |
|---|---|---|
Market Cap | $622.84B | $94.90B |
Volume | 5,277,426 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $278.43 | $376.23 |
52-Week Low | $186.00 | $149.83 |
Typical Hold Time | 129 Days | 39 Days |
Enterprise Value | $651.12B | $95.12B |
Dividend Yield | 2.07% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, up 0.67% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net income margin and 25.74% ROE, though valuation metrics appear elevated with P/E of 29.98. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales and Q3 earnings anticipation.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and elevated valuation. Analyst consensus targets $286.53 (11.7% upside) with 52.5% buy ratings. Key risks include biosimilar competition for Stelara and debt-to-asset ratio increase to 24.06% in 2025.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
